Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

September 22, 2017: By Jon Swedien

GraybugGraybug Vision has begun dosing patients in a Phase I/II clinical trial for GB-102, its lead product candidate for wet age-related macular degeneration (AMD), the Redwood City, California, company announced Sept. 19.

GB-102 is a novel intravitreal (IVT) injectable depot formulation of sunitinib malate, a tyrosine kinase inhibitor that blocks multiple angiogenesis pathways. GB-102 has the potential to be a twice annual treatment for wet AMD, Graybug said.

The two-part study—ADAGIO—will evaluate wet AMD patients currently being treated with available IVT anti-VEGF agents who are then switched over to treatment with GB-102 alone, Graybug said.

Part one is a multicenter, open-label, single IVT injection study of up to four dose levels of GB-102 administered in ascending dosing cohorts, Graybug said. Following the single IVT injection of GB-102, patients will undergo monthly evaluation for eight months to assess safety, tolerability, and functional/pharmacodynamic parameters, including visual acuity and optical coherence tomography (OCT) measures of the retina, Graybug said.

Part two is a multicenter, double-masked, randomized, parallel-group, safety, and efficacy evaluation of repeated IVT injections of two dose levels of GB-102 compared with a standard IVT regimen of aflibercept, Graybug said.

Graybug said it also has a second-generation product under development, GB-103, that has potential to be a once-per-year IVT treatment for wet AMD.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022